PURPOSE: To evaluate the changes in the incidence of subconjunctival hemorrhage, hyperemia, photophobia, flap displacements, and flap retractions in myopic patients who have undergone LASIK with an IntraLase 15-kHz femtosecond laser (intraLASIK) with or without the application ofbrimonidine tartrate0.2% in one eye. METHODS:Two hundred eyes of 100 myopic patients were enrolled in this brimonidine tartrate fellow eye control study. These myopic patients were treated with the intraLASIK technique in both eyes. Only 1 eye was treated with brimonidine tartrate 0.2% 30 minutes before surgery. One day after surgery, subconjunctival hemorrhage, photophobia, and hyperemia were evaluated. Flap slippage and flap retractions were evaluated 1 day, 1 week, 1 month, and 3 months after surgery. RESULTS: Of the 100 eyes treated with brimonidine tartrate before intraLASIK, 3 (3%) eyes showed subconjunctival hemorrhage. Complex hyperemia-photophobia was found in 8 (8%) of 100 eyes immediately after the surgery compared with non-brimonidine tartrate treated eyes (79% and 92%, respectively). Eyes treated with brimonidine showed no incidence of flap complications, whereas eyes not treated with brimonidine showed 11% flap retraction. CONCLUSIONS: This study suggests that brimonidine tartrate 0.2% administered before intraLASIK provides a reduction in the incidence of subconjunctival hemorrhage, hyperemia, and photophobia without increasing flap complications. Copyright 2010, SLACK Incorporated.
RCT Entities:
PURPOSE: To evaluate the changes in the incidence of subconjunctival hemorrhage, hyperemia, photophobia, flap displacements, and flap retractions in myopic patients who have undergone LASIK with an IntraLase 15-kHz femtosecond laser (intraLASIK) with or without the application of brimonidine tartrate 0.2% in one eye. METHODS: Two hundred eyes of 100 myopic patients were enrolled in this brimonidine tartrate fellow eye control study. These myopic patients were treated with the intraLASIK technique in both eyes. Only 1 eye was treated with brimonidine tartrate 0.2% 30 minutes before surgery. One day after surgery, subconjunctival hemorrhage, photophobia, and hyperemia were evaluated. Flap slippage and flap retractions were evaluated 1 day, 1 week, 1 month, and 3 months after surgery. RESULTS: Of the 100 eyes treated with brimonidine tartrate before intraLASIK, 3 (3%) eyes showed subconjunctival hemorrhage. Complex hyperemia-photophobia was found in 8 (8%) of 100 eyes immediately after the surgery compared with non-brimonidine tartrate treated eyes (79% and 92%, respectively). Eyes treated with brimonidine showed no incidence of flap complications, whereas eyes not treated with brimonidine showed 11% flap retraction. CONCLUSIONS: This study suggests that brimonidine tartrate 0.2% administered before intraLASIK provides a reduction in the incidence of subconjunctival hemorrhage, hyperemia, and photophobia without increasing flap complications. Copyright 2010, SLACK Incorporated.